Does COVID-19 affect thyroid more than non-COVID-19 infections? A retrospective study
Author:
Ucal Yasemin1ORCID, Serdar Muhittin1ORCID, Karpuzoğlu Hande2ORCID, Yurttutan Uyar Neval23ORCID, Kilercik Meltem12ORCID, Serteser Mustafa12ORCID, Ozpinar Aysel1ORCID
Affiliation:
1. Department of Medical Biochemistry, School of Medicine , Acibadem Mehmet Ali Aydinlar University , Istanbul , Türkiye 2. Acibadem Labmed Clinical Laboratories , Istanbul , Türkiye 3. Department of Medical Microbiology, School of Medicine , Acibadem Mehmet Ali Aydinlar University , Istanbul , Türkiye
Abstract
Abstract
Objectives
To evaluate the thyroid hormone levels and infection markers in COVID-19 patients and compare them to those in non-COVID-19 patients with infection in a large retrospective dataset.
Methods
In this study, thyroid-stimulating hormone (TSH), thyroid hormones (free T3 and free T4), and several infection markers were reviewed. The study group was divided into three groups that had no thyroid-related disorders: control patients (Group 0; n=7,981), COVID-19 patients (Group 1; n=222), and non-COVID-19 patients with infection (Group 2; n=477). The data were assessed for correlation and group comparisons.
Results
There was a reduction in median (25th–75th percentile) fT3 levels in COVID-19 patients 4.17 pmol/L (3.46–4.85) compared to non-COVID-19 patients with infection 4.65 pmol/L (4.12–5.15), p<0.0001. We detected a negative correlation between fT3 and neutrophil-to-lymphocyte ratio (NLR) in Group 1 (r=−0.534) and Group 2 (r=−0.346) (p<0.0001), indicating a relatively stronger link between fT3 and NLR in COVID-19 patients than non-COVID-19 patients with infection. Additionally, the fT3 levels remained significantly different between study groups when the model was adjusted for age, gender, and infection markers.
Conclusions
COVID-19 and non-COVID-19 infections are associated with low fT3 levels, which likely represent the suppression of the hypothalamic-pituitary-thyroid axis from non-thyroidal illness syndrome.
Publisher
Walter de Gruyter GmbH
Reference31 articles.
1. Zhu, N, Zhang, D, Wang, W, Li, X, Yang, B, Song, J, et al.. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017. 2. World Health Organization. COVID-19 weekly epidemiological update; 2023. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-september-2023. 3. Ni, W, Yang, X, Yang, D, Bao, J, Li, R, Xiao, Y, et al.. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020;24:422. https://doi.org/10.1186/s13054-020-03120-0. 4. Zamorano Cuervo, N, Grandvaux, N. ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife 2020;9:e61390. https://doi.org/10.7554/eLife.61390. 5. Li, M-Y, Li, L, Zhang, Y, Wang, X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 2020;9:45. https://doi.org/10.1186/s40249-020-00662-x.
|
|